An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Publication
, Conference
Voorhees, PM; Schlossman, RL; Gasparetto, CJ; Berdeja, JG; Morris, J; Jacobstein, DA; Anderson, KC; Mitsiades, CS; Laubach, JP; Richardson, PG
Published in: BLOOD
December 6, 2014
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Voorhees, P. M., Schlossman, R. L., Gasparetto, C. J., Berdeja, J. G., Morris, J., Jacobstein, D. A., … Richardson, P. G. (2014). An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.
Voorhees, Peter M., Robert L. Schlossman, Cristina J. Gasparetto, Jesus G. Berdeja, John Morris, Douglas A. Jacobstein, Kenneth C. Anderson, Constantine S. Mitsiades, Jacob P. Laubach, and Paul G. Richardson. “An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.
Voorhees PM, Schlossman RL, Gasparetto CJ, Berdeja JG, Morris J, Jacobstein DA, et al. An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. In: BLOOD. AMER SOC HEMATOLOGY; 2014.
Voorhees, Peter M., et al. “An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.
Voorhees PM, Schlossman RL, Gasparetto CJ, Berdeja JG, Morris J, Jacobstein DA, Anderson KC, Mitsiades CS, Laubach JP, Richardson PG. An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. BLOOD. AMER SOC HEMATOLOGY; 2014.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology